There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Seres Therapeutics (MCRB – Research Report) and Inmune Bio (INMB – Research Report) with bullish sentiments.
Seres Therapeutics (MCRB)
In a report released today, Keay Nakae from Chardan Capital reiterated a Buy rating on Seres Therapeutics, with a price target of $10.00. The company’s shares closed last Tuesday at $4.29, close to its 52-week low of $4.17.
According to TipRanks.com, Nakae is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of
Currently, the analyst consensus on Seres Therapeutics is a Strong Buy with an average price target of $11.67.
See the top stocks recommended by analysts >>
Inmune Bio (INMB)
Maxim Group analyst Jason McCarthy maintained a Buy rating on Inmune Bio yesterday and set a price target of $22.00. The company’s shares closed last Tuesday at $7.85.
According to TipRanks.com, McCarthy ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of
Inmune Bio has an analyst consensus of Strong Buy, with a price target consensus of $17.33.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on MCRB:
